AdAlta and SYNthesis to form AdCella for advanced cancer treatments
ImmunotherapyPhase 1Phase 3Cell TherapyAcquisition
Preview
Source: Pharmaceutical Technology
AdCella will focus on identifying partners with the capability to develop multi-functional cellular immunotherapies. Credit: Lightspring/Shutterstock.com.
The collaboration will introduce cellular immunotherapies from Asia to Western markets, utilising AdAlta’s i-body technology.
The partnership addresses the challenges of solid tumour treatments through enhanced cellular immunotherapies.
The MOU expands AdAlta’s clinical stage pipeline in the field of cellular immunotherapy.
AdCella will identify partners with the capability to develop multi-functional cellular immunotherapies for solid cancers.
See Also:
Medicxi and Starpharma to develop dendrimer-based cancer treatments
Preview
Source: Pharmaceutical Technology
AstraZeneca reports positive Phase III results for Imfinzi in small cell lung cancer
Preview
Source: Pharmaceutical Technology
The MOU outlines a six-month collaboration period, extendable by a further six months, during which AdAlta and SYNBV will conduct due diligence and negotiate final agreements for asset selection.
Upon successful asset acquisition, AdAlta will hold a 75% ownership of AdCella, with SYNBV holding the remaining 25% before the next financing round.
SYNBV managing director Professor Andrew Wilks stated: “We believe that this collaboration will further our fund’s strategy of investing in promising early-stage science by leveraging the inherent advantages of the Australian biotech ecosystem.”
AdCella’s goal is to license or acquire global commercialisation rights of the developed products outside Asia in return for carrying out clinical trials in Australia and integrating AdAlta’s i-body technology into its future product pipeline.
AdAlta CEO and managing director Tim Oldham stated: “As part of our stated strategy to expand our clinical-stage pipeline with assets that work with our i-body platform, we have identified a unique and exciting opportunity to bring highly innovative cellular immunotherapies to Australian patients.”
The partnership offers partner companies an opportunity to access Australia’s clinical and manufacturing ecosystem, AdAlta’s clinical trial capabilities and the i-body platform.
Last month, AdAlta announced results from its Phase I extension study of lead asset AD-214, which is being developed for fibrotic diseases including the debilitating and fatal disease, idiopathic pulmonary fibrosis.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.